GlassScriptPhysician profile
Adil Niaz
NPI 1437685948
$31,462.95
in general payments reported to CMS, 2019-2025
31 companies · $28K in 2025
The $28K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.60 · 2023: $997 · 2024: $2,517 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $5,719 · Consulting Fee: $1,525 · Travel and Lodging: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,912.50 |
| Food and Beverage | $5,718.76 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $270.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,762.79 | 2023-2025 | |
| Pfizer INC. | $12,167.58 | 2023-2025 | |
| Ucb, INC. | $362.24 | 2020-2025 | Briviact, Fintepla, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $322.54 | 2023-2025 | Ajovy, Austedo Xr |
| Lundbeck LLC | $220.75 | 2023-2025 | Vyepti |
| Neurelis, INC. | $175.18 | 2024-2025 | Valtoco |
| Amgen INC. | $158.69 | 2023-2024 | Aimovig |
| Novocure INC. | $130.97 | 2023-2025 | Optune, Optune Gio |
| Tanabe Pharma America, INC. | $128.75 | 2024-2025 | Radicava |
| Scilex Pharmaceuticals INC. | $110.55 | 2024 | |
| Servier Pharmaceuticals LLC | $101.17 | 2024-2025 | |
| Impel Pharmaceuticals INC. | $98.21 | 2023 | Trudhesa |
| Lilly USA, LLC | $96.10 | 2023-2024 | Emgality, Reyvow |
| Tonix Medicines, INC. | $77.04 | 2024-2025 | Zembrace Symtouch |
| Axsome Therapeutics, INC. | $74.58 | 2025 | Symbravo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $71.59 | 2024-2025 | Ingrezza |
| Argenx US, INC. | $68.85 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $46.68 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $35.72 | 2024-2025 | Xeomin |
| Amneal Pharmaceuticals LLC | $35.17 | 2024-2025 | Crexont, Rytary |
| Acadia Pharmaceuticals INC | $34.15 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $31.92 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $31.86 | 2024-2025 | |
| Livanova USA, INC. | $20.57 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $18.16 | 2025 | Qalsody, Spinraza |
| Kyowa Kirin, INC. | $16.65 | 2024 | Nourianz |
| Aucta Pharmaceuticals, INC. | $16.46 | 2025 | Motpoly Xr |
| Otsuka America Pharmaceutical, INC. | $16.06 | 2023 | Nuedexta |
| W. L. Gore & Associates, INC. | $15.19 | 2025 | Gore Cardioform Septal Occluder |
| Springworks Therapeutics, INC. | $13.57 | 2024 | |
| Impel Pharmaceuticals LLC | $3.21 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Niaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.